Dr Philip Bruce Meltmar, AUD | |
480 Central Ave Bldg 1750, Jbphh, HI 96860-4908 | |
(808) 474-0625 | |
Not Available |
Full Name | Dr Philip Bruce Meltmar |
---|---|
Gender | Male |
Speciality | Audiologist |
Location | 480 Central Ave Bldg 1750, Jbphh, Hawaii |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1861484057 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
231H00000X | Audiologist | 147-000600 (Illinois) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Philip Bruce Meltmar, AUD 315 Canyonside Way, Oceanside, CA 92054-7148 Ph: (760) 725-1637 | Dr Philip Bruce Meltmar, AUD 480 Central Ave Bldg 1750, Jbphh, HI 96860-4908 Ph: (808) 474-0625 |
News Archive
In a study to be presented on February 16 between 8 a.m., and 10 a.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting -, in San Francisco, researchers will report findings that suggest shifting from a traditional model of obstetrical care to a laborist model improves pregnancy outcomes.
A research group supported by the National Institutes of Health (NIH) has uncovered a new route for attacking the human immunodeficiency virus (HIV) that may offer a way to circumvent problems with drug resistance. In findings published today in the online edition of the Proceedings of the National Academy of Sciences, the researchers report that they have blocked HIV infection in the test tube by inactivating a human protein expressed in key immune cells.
Scientists have shed light on why some people crave salty food, even when they know it can seriously damage their health.
Cancer patients across the country have a new way to navigate through difficult treatment decisions and communicate better with their doctors. "Open to Options," which recently launched nationally, was developed in conjunction with UCSF to guide patients in making critical health decisions.
CTI BioPharma Corp. and Servier today announced that the pivotal Phase III study evaluating PIXUVRI® combined with rituximab in comparison to gemcitabine combined with rituximab in patients with aggressive B-cell non-Hodgkin lymphoma did not meet its primary endpoint of improvement of progression-free survival
› Verified 7 days ago
Barbara Gordon-wendt, PHD Audiologist Medicare: Not Enrolled in Medicare Practice Location: Naval Health Clinic Hawaii, 480 Central Ave, Jbphh, HI 96860 Phone: 808-257-1861 |